Index RUT P/E - EPS (ttm) -0.97 Insider Own 41.05% Shs Outstand 43.91M Perf Week -10.33%
Market Cap 471.41M Forward P/E - EPS next Y -1.98 Insider Trans 19.63% Shs Float 37.61M Perf Month 6.16%
Income -45.08M PEG - EPS next Q -0.31 Inst Own 42.88% Short Float 10.38% Perf Quarter -5.63%
Sales 0.00M P/S - EPS this Y -54.67% Inst Trans 72.24% Short Ratio 6.12 Perf Half Y 214.42%
Book/sh 3.62 P/B 2.04 EPS next Y -52.10% ROA -24.56% Short Interest 3.90M Perf Year 40.21%
Cash/sh 3.56 P/C 2.07 EPS next 5Y - ROE -26.75% 52W Range 2.18 - 13.68 Perf YTD 62.39%
Dividend Est. - P/FCF - EPS past 5Y 48.33% ROI -19.15% 52W High -45.99% Beta 0.85
Dividend TTM - Quick Ratio 17.99 Sales past 5Y 0.00% Gross Margin - 52W Low 238.94% ATR (14) 0.53
Dividend Ex-Date - Current Ratio 17.99 EPS Y/Y TTM 20.14% Oper. Margin 0.00% RSI (14) 49.47 Volatility 6.92% 6.81%
Employees 42 Debt/Eq 0.02 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 20.19
Option/Short Yes / Yes LT Debt/Eq 0.02 EPS Q/Q -83.99% Payout - Rel Volume 0.25 Prev Close 7.12
Sales Surprise - EPS Surprise -10.66% Sales Q/Q - Earnings May 09 BMO Avg Volume 638.07K Price 7.39
SMA20 4.01% SMA50 -6.96% SMA200 36.07% Trades
Volume 96,384 Change 3.78%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-03-24 Initiated Leerink Partners
Outperform
$25
Nov-17-23 Upgrade Citigroup
Neutral → Buy
$4.50
Oct-19-22 Initiated Guggenheim
Buy
$12
Feb-15-22 Downgrade William Blair
Outperform → Mkt Perform
Feb-10-21 Initiated JMP Securities
Mkt Outperform
Feb-01-21 Initiated William Blair
Outperform
$29
May-09-24 01:55PM
07:00AM
Mar-20-24 01:32PM
Mar-14-24 09:53PM
05:32PM
04:05PM
Loading…
04:05PM
Mar-11-24 04:05PM
Mar-06-24 04:05PM
Feb-20-24 01:47PM
Feb-19-24 01:48PM
Feb-16-24 04:20PM
Feb-14-24 06:15AM
Feb-13-24 04:18PM
Feb-12-24 07:00AM
Nov-14-23 07:00AM
04:05PM
Loading…
Nov-01-23 04:05PM
Oct-03-23 04:05PM
Aug-31-23 04:05PM
Aug-10-23 07:00AM
Aug-07-23 09:22AM
Jul-25-23 09:59AM
07:00AM
Jul-17-23 04:05PM
Jun-21-23 04:05PM
May-15-23 07:00AM
Mar-28-23 04:05PM
Mar-14-23 07:00AM
Feb-07-23 04:05PM
Nov-21-22 04:05PM
Nov-10-22 07:00AM
04:05PM
Loading…
Nov-07-22 04:05PM
Oct-20-22 08:00AM
Oct-19-22 04:05PM
Sep-16-22 01:00PM
Sep-14-22 07:04AM
07:01AM
Aug-11-22 04:05PM
Jul-28-22 04:05PM
Jun-28-22 08:00AM
06:05AM
Jun-02-22 08:00AM
May-19-22 08:00AM
May-12-22 07:00AM
Apr-29-22 06:27AM
Apr-13-22 10:40AM
Mar-25-22 07:00AM
Feb-16-22 11:57AM
(American City Business Journals)
Feb-14-22 04:01PM
Jan-19-22 06:53AM
Nov-22-21 07:00AM
Nov-20-21 08:40AM
Nov-15-21 07:00AM
Nov-12-21 07:00AM
Sep-16-21 08:00AM
Sep-02-21 04:01PM
Aug-22-21 10:12AM
Aug-19-21 07:00AM
Aug-12-21 07:00AM
Aug-09-21 08:48AM
Jul-23-21 12:00PM
Jul-08-21 04:01PM
Jun-11-21 07:00AM
Jun-05-21 07:55PM
Jun-02-21 10:56PM
Jun-01-21 04:55AM
May-29-21 10:59PM
May-25-21 05:41PM
May-21-21 09:18AM
May-20-21 04:31PM
May-11-21 07:00AM
May-10-21 04:05PM
Mar-04-21 07:00AM
Mar-01-21 03:54AM
Feb-18-21 04:01PM
Dec-16-20 07:23PM
Dec-15-20 08:00AM
Dec-08-20 07:30AM
Nov-13-20 08:00AM
Nov-10-20 08:00AM
Oct-14-20 10:18PM
Oct-13-20 08:00AM
Sep-21-20 09:58AM
Sep-10-20 08:00AM
Sep-01-20 12:47PM
Aug-11-20 07:00AM
Aug-04-20 08:00AM
Jul-28-20 08:00AM
Jul-20-20 04:15PM
May-29-20 04:05PM
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Flynn James E Director Feb 16 '24 Buy 8.74 4,290,617 37,499,993 6,151,406 Feb 16 02:37 PM THOMAS FRANK E Director Feb 14 '24 Buy 11.00 2,000 22,000 2,000 Feb 15 04:21 PM Shankar Gopi Chief Development Officer Dec 07 '23 Buy 3.73 5,000 18,662 5,000 Dec 08 04:08 PM Celano Michael Chief Financial Officer May 17 '23 Buy 3.73 5,000 18,632 112,746 May 18 02:13 PM BEN-MAIMON CAROLE President and CEO May 17 '23 Buy 3.71 5,000 18,525 266,829 May 18 02:13 PM Truitt Joseph Director May 17 '23 Buy 3.73 2,750 10,258 2,750 May 18 02:12 PM
Index RUT P/E 16.98 EPS (ttm) 0.30 Insider Own 3.67% Shs Outstand 76.51M Perf Week -6.21%
Market Cap 394.68M Forward P/E - EPS next Y -0.15 Insider Trans -0.85% Shs Float 73.70M Perf Month -6.55%
Income 22.85M PEG 0.85 EPS next Q 0.00 Inst Own 90.42% Short Float 5.08% Perf Quarter -29.81%
Sales 304.64M P/S 1.30 EPS this Y -122.92% Inst Trans -4.29% Short Ratio 4.03 Perf Half Y -16.93%
Book/sh 5.76 P/B 0.90 EPS next Y 7.07% ROA 4.93% Short Interest 3.75M Perf Year -30.19%
Cash/sh 3.45 P/C 1.50 EPS next 5Y 20.00% ROE 5.57% 52W Range 4.38 - 8.45 Perf YTD -37.09%
Dividend Est. - P/FCF 2.94 EPS past 5Y 17.20% ROI 5.23% 52W High -38.95% Beta 0.16
Dividend TTM - Quick Ratio 10.49 Sales past 5Y 20.54% Gross Margin 42.89% 52W Low 17.91% ATR (14) 0.23
Dividend Ex-Date - Current Ratio 11.97 EPS Y/Y TTM -22.10% Oper. Margin 4.98% RSI (14) 39.59 Volatility 5.29% 3.53%
Employees 638 Debt/Eq 0.03 Sales Y/Y TTM -35.83% Profit Margin 7.50% Recom 2.67 Target Price 6.75
Option/Short Yes / Yes LT Debt/Eq 0.03 EPS Q/Q -113.18% Payout 0.00% Rel Volume 0.78 Prev Close 4.86
Sales Surprise 3.57% EPS Surprise -183.33% Sales Q/Q -65.07% Earnings May 08 AMC Avg Volume 929.74K Price 5.16
SMA20 -3.23% SMA50 -14.10% SMA200 -20.45% Trades
Volume 435,554 Change 6.14%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-03-23 Resumed Evercore ISI
In-line
$5
Sep-22-21 Downgrade Raymond James
Outperform → Mkt Perform
Aug-21-20 Initiated Evercore ISI
Outperform
$22
Aug-10-20 Initiated JP Morgan
Neutral
$18
Aug-10-20 Initiated Citigroup
Buy
$18
Aug-07-20 Upgrade Raymond James
Mkt Perform → Outperform
$16
Jun-25-20 Initiated Lake Street
Buy
$19
Apr-21-20 Resumed Stephens
Equal-Weight
$14
Oct-23-18 Resumed Raymond James
Mkt Perform
Jul-16-18 Downgrade Stephens
Overweight → Equal-Weight
Nov-02-17 Downgrade Jefferies
Buy → Hold
Feb-09-17 Upgrade Raymond James
Mkt Perform → Outperform
Jun-13-16 Downgrade Raymond James
Outperform → Mkt Perform
Nov-05-15 Reiterated Mizuho
Buy
$12 → $8
May-07-15 Downgrade JMP Securities
Mkt Outperform → Mkt Perform
Jan-23-15 Reiterated Mizuho
Buy
$10 → $12
Jun-12-14 Reiterated Canaccord Genuity
Buy
$10 → $11
Jun-11-14 Reiterated Mizuho
Buy
$9 → $10
Dec-21-12 Initiated Mizuho
Buy
$9
Aug-08-12 Upgrade Barrington Research
Mkt Perform → Outperform
$12.50
Show Previous Ratings
Today 10:47AM
May-10-24 03:04PM
May-09-24 01:54PM
08:29AM
(Thomson Reuters StreetEvents)
03:48AM
08:57PM
Loading…
May-08-24 08:57PM
06:20PM
05:17PM
(Associated Press Finance)
04:05PM
Apr-22-24 08:00AM
Apr-18-24 11:30AM
Mar-21-24 08:31AM
Feb-28-24 09:23AM
(Thomson Reuters StreetEvents) +9.96%
08:55AM
Feb-27-24 05:11PM
(Associated Press Finance)
04:48PM
Loading…
04:48PM
04:05PM
Feb-13-24 04:05PM
Feb-01-24 06:42PM
Jan-04-24 07:05AM
Dec-22-23 05:01AM
Nov-27-23 09:55AM
Nov-13-23 04:15PM
Nov-09-23 11:12AM
Nov-08-23 12:14PM
08:40AM
(Thomson Reuters StreetEvents)
Nov-07-23 06:50PM
05:47PM
(Associated Press Finance)
04:59PM
04:05PM
04:05PM
Loading…
Oct-23-23 04:05PM
Aug-09-23 06:02AM
Aug-05-23 08:52AM
Aug-04-23 11:45AM
(Thomson Reuters StreetEvents) +32.29%
Aug-03-23 05:55PM
04:58PM
(Associated Press Finance)
04:05PM
Jul-20-23 04:05PM
07:05AM
Jun-29-23 07:07AM
Jun-21-23 08:00PM
Jun-13-23 04:05PM
Jun-08-23 11:03AM
Jun-01-23 06:29AM
May-16-23 06:08AM
May-12-23 07:12AM
(Simply Wall St.) -18.67%
May-11-23 11:03AM
(Thomson Reuters StreetEvents)
May-10-23 05:35PM
04:34PM
04:05PM
May-03-23 07:05AM
Apr-26-23 08:00PM
Apr-21-23 09:40AM
Apr-05-23 08:38AM
Mar-29-23 07:30AM
Mar-21-23 07:22AM
Mar-20-23 07:20AM
Mar-08-23 11:53AM
Feb-23-23 12:20PM
Feb-16-23 04:38PM
05:41AM
Feb-15-23 03:48PM
Feb-14-23 06:05PM
04:05PM
Feb-07-23 07:05AM
06:37AM
Dec-21-22 07:52AM
Dec-01-22 07:05AM
Nov-14-22 07:05AM
Nov-08-22 06:05PM
04:05PM
Nov-03-22 09:15AM
Nov-02-22 07:05AM
Nov-01-22 07:05AM
Oct-07-22 09:14AM
Oct-01-22 10:30AM
Sep-28-22 10:28AM
07:05AM
Sep-20-22 04:05PM
Sep-14-22 07:05AM
Aug-31-22 06:29AM
Aug-14-22 08:28AM
Aug-09-22 07:25PM
04:05PM
Aug-02-22 07:05AM
Jul-28-22 07:05AM
Jul-14-22 08:42AM
07:05AM
Jun-14-22 08:31AM
Jun-08-22 04:05PM
May-25-22 07:05AM
May-23-22 04:05PM
May-17-22 07:05AM
May-10-22 06:55PM
04:05PM
May-04-22 06:45PM
May-03-22 04:05PM
Apr-24-22 10:21AM
Apr-07-22 07:05AM
Mar-31-22 07:05AM
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Weber Kathleen Gallagher Chief Product Officer Dec 19 '23 Option Exercise 5.71 4,129 23,597 278,829 Dec 21 04:04 PM Weber Kathleen Gallagher Chief Product Officer Dec 19 '23 Sale 8.05 24,129 194,219 254,700 Dec 21 04:04 PM Anthony Michele Marie SVP Finance & CAO Aug 15 '23 Option Exercise 5.71 1,758 10,038 87,946 Aug 17 04:27 PM Anthony Michele Marie SVP Finance & CAO Aug 15 '23 Sale 6.50 1,758 11,427 86,188 Aug 17 04:27 PM McGrath Kenneth J Chief Financial Officer May 30 '23 Buy 4.93 100,000 492,810 285,512 May 31 04:14 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
